Compare Palo Alto Networks Inc (PANW) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Palo Alto Networks Inc vs TG Therapeutics Inc — how do they compare? Palo Alto Networks Inc trades at $419 (market cap $331.76B), while TG Therapeutics Inc trades at $55 (market cap $8.16B). The key difference: Palo Alto Networks Inc is far larger — about 40.7× TG Therapeutics Inc's market cap, and Palo Alto Networks Inc is trading nearer its 52-week high, TG Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Palo Alto Networks Inc for 82 Days and TG Therapeutics Inc for 16 Days on average.
| PANW | TGTX | |
|---|---|---|
Market Cap | $331.76B | $8.16B |
Volume | 3,886,927 | 1,735,121 |
Sector | Technology | Health |
52-Week High | $419.91 | $59.06 |
52-Week Low | $141.67 | $26.94 |
Typical Hold Time | 82 Days | 16 Days |
Enterprise Value | $331.19B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Palo Alto Networks (PANW) trades at $418.78, up 3.3% with strong technical momentum near 52-week highs. The stock shows bullish moving averages and has consistently beaten earnings estimates in recent quarters. Revenue growth remains robust at $9.22B for 2025, though valuation metrics appear elevated with P/E at 1,013.93 and P/S at 26.99. The company's platformization strategy and AI security services are driving investor optimism.
Outlook remains positive with 72% analyst buy ratings and $398.70 consensus target, though premium valuation and rising costs present risks. AI cybersecurity demand creates growth opportunities, but execution on large customer deals and margin sustainability will be critical for continued upside.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Palo Alto Networks Inc
Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.
Read more on PANW →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
